ARTICLE | Company News
EpiCept cancer, neurology news
January 19, 2009 8:00 AM UTC
EpiCept will reduce headcount by 65% to 13 over the next six months and discontinue its drug discovery operations to focus on registration of Ceplene histamine dihydrochloride in North America. The h...